Ovid Therapeutics Inc OVID

$2.38 -0.05 (-2.06%)

Valuation

Market cap
474,574,000
Revenue TTM
$7,250,000
Net income TTM
$-17,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-240.14%
Debt to equity
0.00

Trading

Volume
2,173,600
Avg volume
1,572,392
Day's range
$2.33 – $2.48
Shares out
195,298,000
Stochastic %K
10%
Beta
0.22
Analysts
Strong Sell
Price target
$5.60

Price

Company profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride...

Show more

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
646 661 7661
Website
https://www.ovidrx.com
Address
Hudson Commons, 441 9th Avenue 14th Floor, New York, United States

Latest news

Stocktwits

RadioIsotope25 Oct 3, 1:44 PM
Shorts are getting burned in $IOVA while they are still short 87.9 million shares and the stock is up 421% YTD. Of all the biotechs with 20 million or more shares short $CATX is only one presenting data in Oct and Nov. stock is trading at Cash+ Real Estate value. https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/catx-ex99_1.htm $OVID $VKTX
0 replies
lucabrix Oct 2, 7:14 PM
$OVID Incredible price!!!
0 replies
michaelhearn Oct 1, 2:12 AM
$OVID institutions own almost 81% of this. And climbing. Pretty safe hold in a turbulent market
0 replies
Dubbyy Sep 11, 4:13 PM
$OVID Check out this article from TipRanks | Ovid Therapeutics price target raised to $5 from $4 at H.C. Wainwright | https://tipranks.onelink.me/WJho/cst8zjvk
0 replies
Dubbyy Sep 4, 3:17 AM
$OVID https://tipranks.onelink.me/WJho/eksopv33
1 replies
luccichio Aug 28, 2:22 PM
$OVID three today? After hours maybe ..
0 replies
StockConsultant Aug 26, 3:37 AM
$OVID Therapeutics stock, watch for a top of range breakout at https://www.stockconsultant.com/?OVID Breakout trade WATCH for possible breakout above 2.97 Target: 3.44, 18.2% Stop: 2.76 Loss: 5.2% P/L ratio: 3.5 : 1 - Excellent BULLISH [Timing] Strong bullish 3 day candlestick pattern. [Timing] breakout watch above 2.97, no resistance in area just above. BEARISH [Positioning] Intermediate trend possibly bearish, Sideways trend near upper resistance. [Positioning] at resistance
0 replies
lucabrix Aug 25, 3:10 PM
$OVID Reply!
0 replies